biogen

The drug was discontinued by Biogen after inconsistent trial data, concerning side effects including brain swelling, and poor financial outlook.

More than 300 current and former biotech and pharmaceutical executives have signed an open letter criticizing a federal ...

The Veterans Health Administration (VHA) will provide coverage for Japanese company Eisai Co., Ltd and Biogen's Alzheimer’s treatment Leqembi to ...

Pharmaceutical giant Biogen has agreed to pay $900 million to settle claims that it paid kickbacks to physicians ...

Analysis Aduhelm is the brand name under which the Alzheimer’s drug Aducanumab is marketed. It is developed by ...

Biogen Inc. and Japanese partner Eisai Co. said on Thursday the U.S. Food and Drug Administration (FDA) had ...

Biogen Inc. on Monday cut the price of its Alzheimer's drug by about half to $28,200 for an ...

As physicians and health policy experts debate the merits of Aduhelm, the first new drug approved for Alzheimer’s ...

The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its ...

Government health officials on Monday approved Biogen's aducanumab as the first treatment to attack a likely cause of ...

Fifteen new coronavirus cases in Massachusetts are linked to a conference held by Biogen in Boston last month, ...

Biogen and partner Eisai Co. Ltd. are ending two late-stage trials for the experimental Alzheimer's drug aducanumab, in ...